Novartis, CH0012005267

RBC sets a CHF 120.00 target for Novartis stock

Published on 10/26/2026 at 16:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novartis has results due October 27, 2026. Novartis stock costs EUR 137.74 on October 26, 2026, minus 0.75 percent versus Xetra close.

Analyst target and reporting date

RBC maintained a Neutral rating and a CHF 120.00 target on October 23, 2026.
Consensus projects USD 14.90 billion in third-quarter sales versus USD 13.91 billion a year earlier.
Novartis stock costs EUR 137.74 at Lang & Schwarz on October 26, 2026 at 4:39 p.m. CEST, minus 0.75 percent versus the Xetra close of October 23, 2026 at EUR 138.78.
Third-quarter results are scheduled for October 27, 2026.

Novartis, CH0012005267, Illustration mit AI erstellt.

Novartis (ISIN CH0012005267) faces a CHF 120.00 target from RBC, which maintained a Neutral rating on October 23, 2026, according to MarketScreener. The target is below the latest Swiss price of CHF 128.00 from October 23, 2026. Novartis stock was trading at EUR 137.74 at Lang & Schwarz on October 26, 2026 at 4:39 p.m. CEST, minus 0.75 percent versus the Xetra close of October 23, 2026 at EUR 138.78.

Sales estimates set the next test

Novartis is scheduled to report third-quarter results on October 27, 2026. The company lists the reporting date in its investor calendar, which also identifies Basel as the reporting location, according to Novartis.

MarketWatch reported on October 26, 2026 that consensus calls for third-quarter sales of USD 14.90 billion, compared with USD 13.91 billion in the same quarter a year earlier. The same preview puts expected core operating profit at USD 5.61 billion, versus USD 5.46 billion for the prior-year quarter.

Stock remains below the Swiss high

On the Swiss Exchange, Novartis closed at CHF 128.00 on October 23, 2026. The quoted 52-week range was CHF 97.05 to CHF 132.68, placing that close CHF 4.68 below the high and CHF 30.95 above the low. The range and the session figures were listed for the same date.

The euro quotation sits below the Xetra close, while the Swiss share had gained 15.97 percent since the start of 2026 by October 26, 2026. The difference between the German and Swiss quotations reflects the separate currencies and venues, not one combined daily return.

What does RBC's target imply?

RBC's CHF 120.00 target is CHF 8.00 below the CHF 128.00 Swiss close, a 6.25 percent difference calculated against that close. MarketScreener also listed a Hold consensus from 23 analysts and an average target of USD 149.72, with the consensus dated October 26, 2026.

The next scheduled corporate date is October 27, 2026, when Novartis is due to publish its third-quarter figures. That release will provide the first direct comparison with the USD 14.90 billion sales estimate and the USD 5.61 billion core operating profit forecast.

Price and upcoming results

Novartis stock was trading at EUR 137.74 at Lang & Schwarz on October 26, 2026 at 4:39 p.m. CEST, minus 0.75 percent versus the Xetra close of October 23, 2026 at EUR 138.78. The further course of trading is shown by the continuously updated real-time quote of Novartis stock.